Cargando…
Hallmarks of Resistance to Immune-Checkpoint Inhibitors
Immune-checkpoint inhibitors (ICI), although revolutionary in improving long-term survival outcomes, are mostly effective in patients with immune-responsive tumors. Most patients with cancer either do not respond to ICIs at all or experience disease progression after an initial period of response. T...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381103/ https://www.ncbi.nlm.nih.gov/pubmed/35362046 http://dx.doi.org/10.1158/2326-6066.CIR-20-0586 |